TP53 and breast carcinoma: Almodóvar et al. (27) analyzed the expression of TRAIL receptors in the MCF-7 (TP53 wild-type) and the EVSA-T (TP53-mutated) breast cancer cell lines before and after treatment with doxorubicin.